Conference Coverage

Diabetes from checkpoint inhibitors probably means lifelong insulin


 

REPORTING FROM ENDO 2018


The median age at diabetes presentation was 61 years and ranged from 32 to 82 years. The majority of patients were men, which reflects MD Anderson demographics, not a predisposing risk factor, Dr. Iyer said.

Melanoma was the most common cancer, followed by renal cell and prostate; patients had stage 2-4 disease. About half the subjects were on single agent anti-PD-1 treatment, about a third on anti-PD-1 combination treatment, and the rest on anti-PD-L1 combination therapy. C-peptide levels were below 0.9 ng/mL at diabetes diagnosis in most of the patients. Eleven of the 20 tested (55%) were positive for the pancreatic islet cell antibody GAD65.

The investigators had no disclosures. A funding source was not reported.

SOURCE: Iyer PC et al. Abstract OR05-5.

Pages

Recommended Reading

Award for best hospital goes to … the Mayo Clinic
MDedge Hematology and Oncology
Many years on metformin linked to anemia risk
MDedge Hematology and Oncology
Does incretin therapy increase pancreatic cancer risk?
MDedge Hematology and Oncology
Empagliflozin’s heart failure benefits linked to volume drop
MDedge Hematology and Oncology
New hematologic, cardiovascular system link may have therapeutic implications
MDedge Hematology and Oncology
NASH rapidly overtaking hepatitis C as cause of liver cancer
MDedge Hematology and Oncology
MDedge Daily News: Have ‘The Talk’ about medical marijuana
MDedge Hematology and Oncology
MDedge Daily News: Treating H. pylori slashed new gastric cancers
MDedge Hematology and Oncology
MDedge Daily News: Why low-calorie sucralose may fuel weight gain
MDedge Hematology and Oncology
MDedge Daily News: How European data privacy rules may cost you
MDedge Hematology and Oncology